 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
A case of pneumonia caused by Bordetella hinzii |
| Language |
J |
| AuthorList |
Honami Ando, Ataru Moriya, Ayano Motohashi, Ryo Ishikawa, Yuka Takahashi, Erina Isaka, Masami Kurokawa, Kazuhisa Mezaki, Keiko Nagashima, Michi Shoji, Mitsuru Ozeki, Takahito Nakamoto, Kei Yamamoto, Norio Omagari |
| Affiliation |
Microbiology Laboratory, Central Laboratory, National Center for Global Health and Medicine Hospital |
| Publication |
J.J.C.M.: 33 (3), 189-195, 2023 |
| Received |
December 13, 2022 |
| Accepted |
March 20, 2023 |
| Abstract |
A 70-years-old man under treatment for COVID-19 experienced bacterial pneumonia thought to be caused by Bordetella hinzii during hospitalization. This case was using dexamethasone for COVID-19 treatment and had underlying diabetes and liver disease. B. hinzii presents small Haemophilus-like negative bacilli in Gram staining, grows on blood agar, chocolate agar, and BTB lactose agar, and after 48 hours forms characteristic flat colonies with raised centers and margins, and it is possible to identify the species by mass spectrometry. On the other hand, it is identified as Bordetella avium by biochemical characterization using API20NE, but B. hinzii can be presumed from n-capric acid and phenyl acetate resolution. In addition, it is possible to estimate this bacterium by showing resistance trends to many cephalosporins by drug susceptibility tests. In an additional study, ribotest pertussis using strains showed cross-reactivity between B. hinzii and related bacteria. When using Ribotest pertussis, understanding of cross-reactivity including this bacterium and understanding of differences in clinical symptoms can prevent erroneous notifications under the Infectious Diseases Control Law. |
| Keywords |
Bordetella hinzii, API20NE |
|
